SHORT IPLEX DESCRIPTION:
iPlex is an injectable IGF-1 medication, developed for market in the U.S. by Insmed Incorporated. iPlex is likely to market very soon in the United States for the treatment of children with growth failure caused by Severe Primary IGF-1 deficiency (Primary IGFD). This type of growth deficiency is categorized by an inability of the body to properly respond to Growth Hormone with IGF-1 synthesis. IGF-1 can be a very potent growth promoting drug. Properly used, its results can be quite remarkable in many cases.
LONG IPLEX DESCRIPTION:
iPlex is an injectable IGF-1 medication, developed for market in the U.S. by Insmed Incorporated of Glen Allen Virginia. The technology itself was designed and licensed from the firm Celtrix. iPlex contains a mixture of recombining human IGF-1 and recombinant human IGFBP-3 (rhIGF-1/rhIGFBP-3). Since IGF-1 easily disassociates from this binding protein, the mixture provides all of the biological effects of Insulln-like Growth Factor 1 on growth and metabolism. Mecasermin Rinfibate seeks to remedy a principle deficit of Mecasermin, which is a straight recombinant IGF-1 hormone product. This deficit is a rapid rate of metabolic clearance, which gives IGF-1 a very short half-life in the body. As a result Mecasermin needs to be injected twice daily in order for therapeutic blood levels to be maintained. Although exact dosing regimens remain to be elucidated, iPlex should require a notably more favorable schedule, which should be welcome by anyone that doesn’t find favor in 2 injections each and every day.
iPlex is likely to market very soon in the United States for the treatment of children with growth failure caused by Severe Primary IGF-1 deficiency (Primary IGFD). This type of growth deficiency is categorized by an inability of the body to properly respond to Growth Hormone with IGF-1 synthesis. Such patients usually have low IGF-1 levels and high GH levels. The FDA officially approved iPlex for this treatment in September 2005, although Insmed still needs to satisfy a number of documentation requests before the drug can officially be sold to patients. It is expected to hit the U.S drug market some time in 2006, following the first U.S. Mecasermin drug (Increlex) only by a year or so. The FDA had granted Orphan Drug status to Insmed in 2004 for using Mecasermin Rinfibate to treat extreme Insulin resistance as well, however, it has not yet been sold or officially approved for this purposes. It is likely that iPlex will be prescribed for both indications within a short period of time.
There is not a whole lot that can be said about iPlex until it is officially released. We do know from experimenting with Long R3 IGF-1 that IGF-1 can be a very potent growth promoting drug. Properly used, its results can be quite remarkable in many cases. Knowing this, iPlex is expected to offer similar strong benefits to athletes and bodybuilder in regards to the promotion of lean muscle tissue gain and strength increases. Much of what is said of GH therapy can be said of IGF-1 (though perhaps more intensely), and this also includes IGF-1 having strong effects on general organ growth and blood sugar regulation. This drug should be respected not only as an effective anabolic, but also as a potentially dangerous agent if misused and abused. IGF-1 use, even a U.S. approved IGF-1 drug like iPlex, is not to be taken lightly. In time we will have more specific information to relay on this drug, pertaining to safe dosing schedules, clinical trial results, and hopefully real world gains with (non-medical) consumers. Until then, this remains a drug of great theoretical interest. We anticipate the release of both it and the rebating medical information in the coming months.